Newsroom

LONDON--(BUSINESS WIRE)--  09-January-2026 Issue: Newday Funding Master Issuer Plc Series 2024-1 Class C RegS XS2768182870 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 15-December-2025 Date To: 15-January-2026 Record Date: 14-January-2026 Value Date: 15-January-2026 Benchmark Rate: 3.84354% Margin: 2.4% Total Rate: 6.24354% Number of Days: 31 Day Count: Actual / 365L Interest Frequency: Monthly Total...

DUBAI, United Arab Emirates--(BUSINESS WIRE)--Seagate Technology plc (NASDAQ: STX), a global leader in mass‑capacity data storage, is showcasing advanced storage solutions at Intersec 2026 that help power the transformation of AI-driven video analytics into searchable, decision‑ready intelligence. The edge-to-cloud portfolio is designed to help businesses unlock the full value of their data and make smarter, faster decisions. AI applications in video image analytics (VIA) are fueling unpreceden...

WIXOM, Mich.--(BUSINESS WIRE)--Rockwell Medical is a viable alternative supplier in the western U.S., serving customers with a reliable supply chain and high-quality products....

LONDON--(BUSINESS WIRE)--  09-January-2026 Issue: Newday Funding Master Issuer Plc Series 2024-1 Class A Reg S XS2768182284 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 15-December-2025 Date To: 15-January-2026 Record Date: 14-January-2026 Value Date: 15-January-2026 Benchmark Rate: 3.84354% Margin: 1.18% Total Rate: 5.02354% Number of Days: 31 Day Count: Actual / 365L Interest Frequency: Monthly Tota...

LIÈGE, Belgium & COPENHAGEN, Denmark--(BUSINESS WIRE)--Bio‑Sourcing and Zerion Pharma A/S today announce that their joint project to develop an oral formulation of Trastuzumab, the pioneer monoclonal antibody used to treat breast cancer, has been awarded funding under EUREKA Eurostars. This is Bio‑Sourcing’s second Eurostars success and, together with Zerion’s breakthrough Dispersome® technology, it will support the development of an oral formulation of an anti‑HER2 antibody for the treatment o...

SANTA CLARA, Calif. & TURIN, Italy--(BUSINESS WIRE)--PlusAI, a leader in AI software for autonomous trucks, announced an expansion of its long-standing partnership with IVECO, the commercial vehicle brand of Iveco Group N.V. (EXM: IVG). Together, the companies will launch the first deployment of heavy-duty trucks equipped with Level 4 Autonomous Driving Systems (ADS) in Southern Europe, in collaboration with Spanish logistics operator Sesé and the Government of Aragon. This announcement comes o...

BELLEVUE, Wash.--(BUSINESS WIRE)--Savers Value Village, Inc. (NYSE: SVV), (the “Company”) today announced preliminary net sales for the fourteen weeks ended January 3, 2026 (the "fourth quarter") and the fifty-three weeks ended January 3, 2026 ("fiscal 2025") in conjunction with the Company’s participation in the ICR Conference January 12-14, 2026. The Company’s results for both the fourth quarter and full year ended January 3, 2026 included the benefit of one additional week (the "53rd week")...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for ivonescimab, the novel, first-in-class investigational bispecific antibody, in combination with chemotherapy in second-line or later treatment of patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-squamous non-...

NEW YORK--(BUSINESS WIRE)--H.C. Wainwright & Co., LLC (“HCW”), a leading investment bank focused on capital markets, equity research, and institutional sales across the life sciences and other high-growth sectors, today announced that Jim Horvath has joined the Firm as Managing Director and Healthcare Equities Sales Specialist. Mr. Horvath brings more than 25 years of experience in institutional healthcare sales, with a proven track record of building and scaling high-impact sales platforms...

MENLO PARK, Calif.--(BUSINESS WIRE)--MedaSystems, the leading SaaS platform for Expanded Access, Post Trial Access, and Investigator Initiated Studies, today announced a milestone year defined by accelerated customer growth, strong clinical adoption, and significant advances in regulatory and AI readiness. The company continued to expand its role as a trusted partner to life sciences organizations and clinicians seeking treatment pathways for patients with urgent medical needs. MedaSystems cont...